[go: up one dir, main page]

WO2017163268A2 - Forme d'administration pharmaceutique du divalproex à libération prolongée - Google Patents

Forme d'administration pharmaceutique du divalproex à libération prolongée Download PDF

Info

Publication number
WO2017163268A2
WO2017163268A2 PCT/IN2017/050107 IN2017050107W WO2017163268A2 WO 2017163268 A2 WO2017163268 A2 WO 2017163268A2 IN 2017050107 W IN2017050107 W IN 2017050107W WO 2017163268 A2 WO2017163268 A2 WO 2017163268A2
Authority
WO
WIPO (PCT)
Prior art keywords
dosage form
divalproex
sustained release
pharmaceutical dosage
release pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2017/050107
Other languages
English (en)
Other versions
WO2017163268A3 (fr
Inventor
Vishal SUHAGIYA
T Nathamani
Amol Kulkarni
Shirish Kulkarni
Rajamannar Thennati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Ltd
Original Assignee
Sun Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Ltd filed Critical Sun Pharmaceutical Industries Ltd
Publication of WO2017163268A2 publication Critical patent/WO2017163268A2/fr
Publication of WO2017163268A3 publication Critical patent/WO2017163268A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Definitions

  • the present invention relates to an improved sustained release compact pharmaceutical dosage form suitable for a once daily administration.
  • Valproic acid and its derivatives are indicated for the treatment of different types of epilepsy, for the treatment of acute manic or mixed episodes associated with bipolar disorder, and for prophylaxis of migraine headaches.
  • a complex constituted by a 1 : 1 molar relationship of valproic acid and sodium valproate (divalproex sodium) has recently reached some preference in the market.
  • Divalproex sodium is marketed by Abbott Laboratories as conventional delayed-release (DR), enteric-coated, dosage forms (Depakote® tablets, and DepakoteTM sprinkle capsules), and as innovative extended release (ER) tablets (DepakoteTM ER).
  • Both tablets are supplied in dosage strengths containing divalproex sodium equivalent to 250 and 500 mg of valproic acid.
  • the main constraint of divalproex-ER is its lower bioavailability in comparison with divalproex-DR.
  • Divalproex sodium has narrow therapeutic window as the range between the effective valproic acid concentrations and the concentrations associated with serious toxicity is narrow; sub-optimal doses or concentrations lead to therapeutic failure or severe toxicity; valproic acid is subject to therapeutic monitoring based on pharmacokinetics measures; and valproic acid has low-to-moderate within-subject variability.
  • a sustained release pharmaceutical dosage form comprising divalproex or its salt that provides an increased oral bioavailability of divalproex or its salt, and therefore, it allows reduction in the total daily dose.
  • the present inventors have found a sustained release pharmaceutical dosage form comprising divalproex or its salt and rate controlling polymer, wherein when one or more units of the sustained release pharmaceutical dosage form comprising a reduced total daily dose of divalproex or its salt, is/are administered once daily, therapeutically effective levels of divalproex for treating acute manic or mixed episodes associated with bipolar disorders with or without pyschotic features, complex partial seizures and simple and complex absence seizures or migraine are obtained.
  • the present invention provides a sustained release pharmaceutical dosage form comprising divalproex or its salt and rate controlling polymer, wherein when one or more units of the sustained release pharmaceutical dosage form comprising a reduced total daily dose of divalproex or its salt, is/are administered once daily, therapeutically effective levels of divalproex for treating acute manic or mixed episodes associated with bipolar disorders with or without pyschotic features, complex partial seizures and simple and complex absence seizures or migraine are obtained.
  • the sustained release pharmaceutical dosage form of the present invention not only provides a reduced dose, but also provides reduced number of units of the dosage form that are to be consumed as compared to that of the commercially available product. DESCRIPTION OF THE FIGURE
  • Figure 1 describes the graph of percentage drug released Vs time in hours when tablet of Example 1 is subjected to in vitro dissolution test in 500 ml of 0.1 N hydrochloric acid for 45 minutes followed by 900 ml of pH 5.5 phosphate buffer with sodium lauryl sulphate 75 mM in USP II apparatus at 100 rotations per minute.
  • the dosage form releases more than 20 % and less than 40 % at the end of 3 hours; releases more than 55 % and less than 65 % at the end of 9 hours and releases more than 65 % and less than 80 % at the end of 12 hours.
  • a reduced total daily dose of divalproex or its salt' means that the total daily dose of divalproex or its salt is less than that recommended for DepakoteTM ER. It means that sustained release pharmaceutical dosage form of the present invention comprises a lesser amount of divalproex or its salt expressed as miligrams of valproic acid as compared to DepakoteTM ER, yet it provides a plasma concentration time profile equivalent to that obtained by administering DepakoteTM ER.
  • the % reduction in the total daily dose may be at least 15 %, preferably at least 20 %, preferably at least 35 %, most preferably 50 %. More particularly the reduction in total daily dose is in the range of 15 to 25%, still more particularly it is 20%.
  • units of sustained release dosage form of the present invention with divalproex or its salt at a dose of 800 mg of valproic acid may provide a plasma concentration time profile equivalent to that obtained by administering DepakoteTM ER units at a dose of 1000 mg.
  • a single units of the sustained release pharmaceutical dosage form may contain 200 mg, 400 mg, 600, 800 mg of divalproex or its salt, expressed as mg of valproic acid, in contrast to 250 mg or 500 mg of divalproex sodium present in the commercially available product available under the name of Depakote ® ER or its equivalent generic products. Table below shows the improvement in .terms of number of tablets the patient needs to ingest:
  • a 250 mg tablet A 200 mg tablet
  • a 500 mg tablet A 400 mg tablet
  • a 250 mg tablet and a 500 mg tablet A 600 mg tablet
  • one or more units of the sustained release pharmaceutical dosage form comprises a reduced total daily dose of divalproex or its salt for treatment of mania, so that the recommended daily dose is at least 15 %, preferably at least 20%, preferably at least 35 %, most preferably at least 20 % reduced than the recommended initial dose is 25 mg/kg/day given once daily for DepakoteTM ER for treatment of mania. More particularly the reduction in total daily dose for treatment of mania is in the range of 15 to 25%, still more particularly it is 20%. Further, the maximum recommended dosage is at least 15 % less than 60 mg kg/day so as to achieve trough plasma concentration between 85 and 125 mcg/mL which provides clinical response for treatment of mania. .
  • total daily dose for treatment of mania is in the range of 15 to 25%, still more particularly it is 20%.
  • total daily dose to be administered for a 70 kg body weight patient may be, 1400 mg instead of 1750 mg as indicated in the labelling instructions for Depakote ® ER.
  • the sustained release pharmaceutical dosage form contains such reduced amount of divalproex or its salt so as to accommodate 1400 mg either in a single unit or in more than one unit, for eg. 600 mg in one unit and 800 mg in second unit to be administered, instead of administering three units
  • total daily dose to be administered for a 70 kg body weight patient may be, 3500 mg instead of 4200 mg as indicated in the labelling instructions for
  • the sustained release pharmaceutical dosage form may contain such reduced amount of divalproex or its salt so as to accommodate about 3500 mg either in a single unit or in more than one unit, for eg. 3 units of 1200 mg to provide 3600 mg; instead of administering eight units of 500 mg of Depakote ® ER and one unit of 250 mg of Depakote ® ER.
  • the sustained release pharmaceutical dosage form comprises a reduced total daily dose of divalproex or its salt for treatment of epilepsy, so that the recommended daily dose is at least 15 % reduced than the recommended initial dose is
  • the maximum recommended dosage is at least 15 %, preferably at least 35 %, most preferably at least 50 % lesser than 60 mg/kg/day so as to achieve plasma concentration between 50 to 100 mcg/mL which range is effective in providing clinical response while treating epilepsy such as complex partial seizures, or simple and complex absence seizures. . More particularly the reduction in total daily dose for treatment of epilepsy is in the range of 15 to 25%, still more particularly it is 20%.
  • a unit of the sustained release pharmaceutical dosage form contains divalproex or its salt, expressed as valproic acid, in amounts of 200 mg, 300 mg, 350 mg, 400 mg, 450 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 950 mg, 1100 mg, 1200 mg, 1250 mg, 1300 mg, 1400 mg or 1500 mg per unit dosage form. In one preferred embodiment, it may be 200 mg, 400 mg, 600 mg, 800 mg and 1200 mg.
  • a single unit of the sustained release pharmaceutical dosage form may contain 200 mg, 400 mg of divalproex or its salt, expressed as mg of valproic acid, in contrast to 250 mg or 500 mg of divalproex sodium present in the commercially available product available under the name of
  • total daily dose to be administered for a 70 kg body weight patient may be, 700 mg instead of 1050 mg.
  • the sustained release pharmaceutical dosage form contains such reduced amount of divalproex or its salt so as to accommodate 700 mg either in a single unit or in more than one unit, instead of administering two units of 500 mg as indicated in the labelling instructions for Depakote ® ER.
  • total daily dose to be administered for a 70 kg body weight patient may be, 2100 mg instead of 4200 mg as indicated in the labelling instructions for Depakote ® ER.
  • the sustained release pharmaceutical dosage form contains such reduced amount of divalproex ® or its salt so as to accommodate 2100 mg either in a single unit or in more than one unit, for eg. 1 unit of 1200 mg and 1 unit of 900 mg; instead of administering eight units of 500 mg of Depakote ® ER and 1 unit of 250 mg of Depakote ® ER.
  • the sustained release pharmaceutical dosage form such that the total units administered once-daily comprise a reduced total daily dose of divalproex or its salt for treatment of migraine, so that the recommended daily dose is at least 15 %, at least 20 %, preferably at least 35 %, most preferably at least 50 % reduced than the currently recommended initial dose for treatment of migraine. More particularly the reduction in total daily dose for treatment of migraine is in the range of 15 to 25%, still more particularly it is 20%.
  • a reduced dose a single 400 mg tablet of the present invention may be administered to the patient to give equivalent therapeutic benefit to 1 unit of 500 mg of
  • a unit of sustained release reduced dosage form of divalproex or its salt of the present invention containing a dose of 200 mg of valproic acid may provide a plasma concentration time profile equivalent to that obtained by administering DepakoteTM ER containing 250 mg of valproic acid.
  • a unit of sustained release reduced dosage form of divalproex or its salt of the present invention containing a dose of 400 mg of valproic acid may provide a plasma concentration time profile equivalent to that obtained by administering DepakoteTM ER containing 500 mg of valproic acid.
  • a unit of sustained release reduced dosage form of divalproex or its salt of the present invention containing a dose of 600 mg of valproic acid may provide a plasma concentration time profile equivalent to that obtained by administering DepakoteTM ER containing 750 mg of valproic acid.
  • a unit of sustained release reduced dosage form of divalproex or its salt of the present invention containing a dose of 800 mg of valproic acid may provide a plasma concentration time profile equivalent to that obtained by administering DepakoteTM ER containing 1000 mg of valproic acid.
  • a unit of sustained release reduced dosage form comprises a dose of 1200 mg of valproic acid equivalent amount of divalproex sodium which may provide a plasma concentration time profile equivalent to that obtained by administering DepakoteTM ER containing 1500 mg of valproic acid.
  • the present invention provides a sustained release pharmaceutical dosage form suitable for once a day administration, a unit of the dosage form comprises divalproex or its salt in an amount equivalent to from 200 to 1500 mg of valproic acid.
  • a unit of the dosage form comprises divalproex or its salt in an amount equivalent to from 200 mg of valproic acid.
  • the present invention also provides a sustained release pharmaceutical dosage form suitable for once a day administration, a unit of the dosage form comprises divalproex or its salt in an amount equivalent to from 400 mg of valproic acid.
  • the present invention provides a sustained release pharmaceutical dosage form suitable for once a day administration, a unit of the dosage form comprises divalproex or its salt in an amount equivalent to from 600 mg of valproic acid. In certain preferred embodiments, the present invention provides a sustained release pharmaceutical dosage form suitable for once a day administration, a unit of the dosage form comprises divalproex or its salt in an amount equivalent to from 800 mg of valproic acid. It also provides a sustained release pharmaceutical dosage form suitable for once a day administration, a unit of the dosage form comprises divalproex or its salt in an amount equivalent to from 1200 mg of valproic acid.
  • the present invention provides a method of treating disease conditions such as acute manic or mixed episodes associated with bipolar disorders with or without pyschotic features, complex partial seizures and simple and complex absence seizures or migraine, by orally administering once a day a sustained release pharmaceutical dosage for, a unit of the dosage form comprising divalproex or its salt in an amount equivalent to from 200 to 1500 mg of valproic acid.
  • a sustained release pharmaceutical dosage form a unit of the dosage form comprising divalproex or its salt in an amount equivalent to 200 mg of valproic acid.
  • the present invention also a method of treating disease conditions such as acute manic or mixed episodes associated with bipolar disorders with or without pyschotic features, complex partial seizures and simple and complex absence seizures or migraine by orally administering once a day a sustained release pharmaceutical dosage form, a unit of the dosage form comprising divalproex or its salt in an amount equivalent to 400 mg of valproic acid.
  • the present invention provides a method of treating disease conditions such as acute manic or mixed episodes associated with bipolar disorders with or without pyschotic features, complex partial seizures and simple and complex absence seizures or migraine by orally administering once a day, a sustained release pharmaceutical dosage form, a unit of the dosage form comprising divalproex or its salt in an amount equivalent to 600 mg of valproic acid.
  • the present invention a method of treating disease conditions such as acute manic or mixed episodes associated with bipolar disorders with or without pyschotic features, complex partial seizures and simple and complex absence seizures or migraine, by orally administering once a day, a sustained release pharmaceutical dosage form, a unit of the dosage form comprising divalproex or its salt in an amount equivalent to 800 mg of valproic acid.
  • It also provides a method of treating disease conditions such as acute manic or mixed episodes associated with bipolar disorders with or without pyschotic features, complex partial seizures and simple and complex absence seizures or migraine, by orally administering once a day, a sustained release pharmaceutical dosage form, a unit of the dosage form comprising divalproex or its salt in an amount equivalent to 1200 mg of valproic acid.
  • the rate controlling polymer used in the sustained release pharmaceutical dosage form of the present invention may be hydrophilic or hydrophobic (water insoluble) polymer or mixtures thereof. Depending upon the release rate controlling capacity, the choice and amount of the hydrophilic or hydrophobic (water insoluble) polymer or mixtures thereof, may be made for obtaining the desired degree of control on release.
  • the suitable examples of the hydrophilic polymer include, but are not limited to, of polyacrylic acids, high viscosity grades of cellulose such as as carbomer, high viscosity grades of cellulose such as hydroxypropyl methyl cellulose K4M, K15M, K 100M wherein the K stands for the USP substitution type 2208 corresponding to a methoxy content of 19 to 24% and a hydroxypropoxy content of 4 to 12%.
  • the high viscosity grades of the hydrophilic polymers are preferred having viscosity in the range of 2000 to 1,50,000 cP.
  • Suitable examples of the water insoluble or hydrophobic polymer include, but are not limited to, waxes, water insoluble cellulose derivatives such as ethyl cellulose, cellulose acetate, cellulose butyrate, insoluble grades of polyacrylates such as methacrylates, acrylic acid copolymers, high molecular weight polyvinyl alcohols.
  • the rate controlling polymer is a mixture of hydrophilic polymer which is a high viscosity grades of hydroxypropyl methyl cellulose K 100M and a polyacrylic acid and the hydrophobic polymer is ethyl cellulose
  • the amount ranges from 10% to 30 % by weight of the sustained release pharmaceutical dosage form of the present invention.
  • the pharmaceutical dosage form is a compressed tablet composition, wherein the divalproex or its salt is intimately mixed with a hydrophobic polymer such as ethyl cellulose.
  • the phase "consists essentially of divalproex or its pharmaceutically acceptable salts and water insoluble polymer as a sole rate controlling polymer. This means that the phase does not contain other excipients that can interfere in controlling the hygroscopicity of the divalproex or its pharmaceutically acceptable salt and/or increase the bulk of the single unit of the sustained release pharmaceutical dosage form composition.
  • the hydrophobic polymer also has a role as to control the dissolution rate and slows the rate of release of divalproex.
  • the hydrophobic polymer is admixed with divalproex or its salt, the amount of hydrophobic polymer ranges from 1 % to 15 % by weight of the tablet, more preferably, in the range of 3 to 12 % by weight of the tablet, most preferably, in the range of 5 % to 10 % by weight of the dosage form which is a compressed tablet.
  • This phase may be a granular or may be a compressed core, which is then further mixed with other rate controlling polymers such as a hydrophobic polymer or a hydrophilic polymer.
  • the divalproex containing phase is a granular phase contains hydrophobic polymer as the sole excipient.
  • This granular phase is surrounded by another phase made up of hydrophilic polymers having high gelling or high viscosity.
  • the water insoluble polymer is present in the range of 1% to 30% by weight of the granular phase, more preferably in the range of 3 % to 20 % and most preferably in the range of 5 % to 15% by weight of the granular phase.
  • the surrounding phase referred to as, extragranular phase is present in an admixture with the granular phase.
  • the extragranular phase comprises one or more hydrophilic polymers such as polyacrylic acids such as carbomer, high viscosity grades of cellulose such as HPMC K4M, HPMC K15M, HPMC K 100M CR.
  • the hydrophilic polymer may be present in the range of 50% to 90% by weight of the extragranular phase, more preferably in the range of 60% to 80% by weight of the extragranular phase and most preferably in the range of 65 % to 78% by weight of the extragranular phase.
  • hydrophilic polymer present in the extragranular phase is a mixture of high viscosity hydroxy propylmethyl cellulose and carboxy vinyl polymer.
  • the present invention provides a sustained release pharmaceutical dosage form comprising divalproex or its salt and rate controlling polymer, wherein when one or more units of the sustained release pharmaceutical dosage form comprising a reduced total daily dose of divalproex or its salt, is/are administered once daily, therapeutically effective levels of divalproex for treating acute manic or mixed episodes associated with bipolar disorders with or without pyschotic features, complex partial seizures and simple and complex absence seizures or migraine are obtained, wherein one unit of the composition comprises a granular phase consisting essentially of divalproex or its pharmaceutically acceptable salts and a water insoluble polymer as a rate controlling polymer, an extragranular phase comprising one or more hydrophilic polymers as a rate controlling polymer, optionally, lubricants, binders and d
  • the extragranular phase further comprises binders and diluents and lubricants.
  • the binders used in the extragranular phase include but are not limited to polyvinyl alcohol, polyvinyl pyrrolidone, pregelatinised starch, sodium alginate, propylene glycol and mixtures thereof.
  • the binders may be present in the range of 1% to 10% by weight of the extragranular phase, more preferably in the range of 1.5% to 8% and most preferably in the range of 2% to 6% by weight of the extragranular phase.
  • the diluents used include but are not limited to lactose, lactitol, microcrystalline cellulose, calcium phosphate tribasic, dextrins, mannitol, and the like and mixtures thereof.
  • the diluents may be present in a range of 1% to 25% by weight of the extragranular phase, more preferably in the range of 2% to 15% and most preferably in the range of 3% to 10% by weight of the extragranular phase.
  • the lubricants used within the scope of this invention include but are not limited to glyceryl behenate, talcum, waxes, hydrogenated castor oil, colloidal silicon dioxide, stearic acid, magnesium stearate and mixtures thereof.
  • the lubricants may be present in the range of 1 to 15% by weight of the extragranular phase, more preferably in the range of 3 to 12% and most preferably in the range of 5 % to 10% by weight of the extragranular phase.
  • the present invention provides a sustained release pharmaceutical dosage form comprising divalproex or its salt and rate controlling polymer, wherein when one or more units of the sustained release pharmaceutical dosage form comprising a reduced total daily dose of divalproex or its salt, is/are administered once daily, therapeutically effective levels of divalproex for treating acute manic or mixed episodes associated with bipolar disorders with or without pyschotic features, complex partial seizures and simple and complex absence seizures or migraine are obtained, wherein one unit of the composition has a drug to polymer ratio is from 90: 10 to 45:55.
  • the sustained release pharmaceutical composition may be prepared any conventional process known in the art.
  • the sustained release pharmaceutical dosage form comprising divalproex or its salt and rate controlling polymer, wherein when one or more units of the sustained release pharmaceutical dosage form comprising a reduced total daily dose of divalproex or its salt, such as 200 mg, 400 mg, 600 mg, 800 mg, 1200 mg is/are administered once daily, therapeutically effective levels of divalproex for treating acute manic or mixed episodes associated with bipolar disorders with or without pyschotic features, complex partial seizures and simple and complex absence seizures or migraine are obtained, when administered with or without food.
  • a reduced total daily dose of divalproex or its salt such as 200 mg, 400 mg, 600 mg, 800 mg, 1200 mg
  • the present invention provides method of treating disease conditions such as acute manic or mixed episodes associated with bipolar disorders with or without pyschotic features, complex partial seizures and simple and complex absence seizures or migraine, wherein a unit sustained release pharmaceutical dosage form comprises 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, 1100 mg, 1200 mg, 1300 mg of vaproic acid equivalent amount of divalproex or its pharmaceutically acceptable salt.
  • a unit sustained release pharmaceutical dosage form comprises 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, 1100 mg, 1200 mg, 1300 mg of vaproic acid equivalent amount of divalproex or its pharmaceutically acceptable salt.
  • the present invention provides a method of treating disease conditions such as acute manic or mixed episodes associated with bipolar disorders with or without pyschotic features, complex partial seizures and simple and complex absence seizures or migraine, wherein a unit sustained release pharmaceutical dosage form comprises 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, 1100 mg, 1200 mg, 1300 mg of vaproic acid equivalent amount of divalproex or its pharmaceutically acceptable salt, the method provides equivalent oral bioavailability when orally administered in fed or fasted state.
  • a unit sustained release pharmaceutical dosage form comprises 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, 1100 mg, 1200 mg, 1300 mg of vaproic acid equivalent amount of divalproex or its pharmaceutically acceptable salt
  • the sustained release pharmaceutical dosage form of the present invention provides a desired degree of control on release, particularly, when subjected to in vitro dissolution in 500 ml of 0.1 N hydrochloric acid for 45 minutes followed by 900 ml of pH 5.5 phosphate buffer with sodium lauryl sulphate 75 mM in USP II apparatus at 100 rotations per minute; the dosage form releases divaproex as follows: a. more than 20 % and less than 40 % at the end of 3 hours and /or
  • the sustained release pharmaceutical dosage form of the present invention is in the form of compressed tablet, granule filled into hard gelatin capsules, mixture of granules and powder filled into a hard gelatin capsule and the like.
  • the sustained release pharmaceutical dosage form of the present invention is a compressed tablet. It is prepared by the process of milling both the active agent, i.e divalproex sodium and hydrophobic polymer for eg. a water insoluble polymer separately in a communiting mill and mixing together in a rapid mixer granulator.
  • the mixture is granulated using a non-aqueous solvent and milled to get the appropriate size in a communiting mill and then dried in a fluid bed drier to form the granular phase.
  • the extragranular phase is prepared by mixing the diluent, one or more hydrophilic polymers, and binder together.
  • the granules of granular phase are mixed with the extragranular phase in a mixer granulator.
  • the mixture thus formed is again granulated using a non-aqueous vehicle and the granules thus formed are reduced to appropriate size in a communiting mill.
  • the granules are dried in a fluid bed granulator at a temperature of 55 °C to 65 °C.
  • the granules are further blended with hydrophilic polymer and lubricants.
  • the lubricated granules are then compressed into tablets and may further be film coated.
  • the sustained release pharmaceutical dosage form composition of the present invention is illustrated in the
  • Table 1 composition of the pharmaceutical dosage form
  • Divalproex sodium was milled through an appropriately sized screen in a communiting mill.
  • Ethyl cellulose was sifted through # 40 sieve and milled divalproex sodium and sifted ethyl cellulose was mixed in a rapid mixer granulator.
  • the mixture was granulated using isopropyl alcohol methylene chloride by mixing the wet mass and the granules were milled through a 10 mm screen using a commuting mill and then dried in a fluid bed drier. The granules were further air dried. Granules were sifted through #16 sieve.
  • stage I granular phase The granules of stage I granular phase were mixed with the extragranular phase of II in a rapid mixer granulator.
  • the material was granulated using a water isopropyl alcohol mixture and the granules thus formed were milled through a 10mm screen using a communiting mill.
  • the granules were dried in a fluid bed granulator at a temperature of 55 to 65° C.
  • the dried granules were sifted through #18 sieve.
  • the granules were further blended with talc, carbomer and magnesium stearate and lubricated with silicon dioxide.
  • the lubricated granules were then compressed into tablets and film coated with a hydroxy propyl methyl cellulose based coating.
  • the tablets prepared as per example 1 were subjected to in vitro dissolution study and in vivo comparative oral bioavailability study.
  • the in vitro dissolution was carried out in 500 ml of 0.1 N Hydrochloric acid for 45 minutes followed by 900 ml of 0.05 M phosphate buffer with 75 mM of sodium lauryl sulphate in USP apparatus II at a rotating speed of 100 rmp.
  • the result is provided as given below:
  • Example 1 containing 800 mg of valproic acid equivalent amount of divalproex sodium (860.80 mg) was subjected to pharmacokinetic study in fed and fasted state. It was compared with two tablets of the commercially available product Depakote ER containing 500 mg of valproic acid valproic acid equivalent amount of divalproex sodium (1076 mg). The results are provided as below:
  • Example 1 containing 800 mg of valproic acid showed extent of absorption that is the same as the extent of absorption obtained with 500 X 2 tablets of commercially available divalproex ER each containing 500 mg of valproic acid. Further, this result is obtained not only in fasted state but also in fed state.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une forme d'administration pharmaceutique à libération prolongée comprenant du divalproex ou son sel et un polymère de régulation du taux, où lorsqu'une ou plusieurs unités de la forme d'administration pharmaceutique à libération prolongée comprenant une dose quotidienne totale réduite de divalproex ou de son sel, est/sont administrées une fois par jour, des taux de divalproex thérapeutiquement efficaces pour traiter les épisodes mixtes ou maniaques aigus associés à des troubles bipolaires avec ou sans caractéristiques psychotiques, crises partielles complexes et crises d'absence simples et complexes ou migraine sont obtenues.
PCT/IN2017/050107 2016-03-23 2017-03-23 Forme d'administration pharmaceutique du divalproex à libération prolongée Ceased WO2017163268A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201621010254 2016-03-23
IN201621010254 2016-03-23

Publications (2)

Publication Number Publication Date
WO2017163268A2 true WO2017163268A2 (fr) 2017-09-28
WO2017163268A3 WO2017163268A3 (fr) 2018-01-11

Family

ID=59899150

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2017/050107 Ceased WO2017163268A2 (fr) 2016-03-23 2017-03-23 Forme d'administration pharmaceutique du divalproex à libération prolongée

Country Status (1)

Country Link
WO (1) WO2017163268A2 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185159A (en) * 1983-07-20 1993-02-09 Sanofi Pharmaceutical composition based on valproic acid and a process for preparing it
US6528090B2 (en) * 1998-12-18 2003-03-04 Abbott Laboratories Controlled release formulation of divalproex sodium
WO2003103635A1 (fr) * 2002-06-07 2003-12-18 Ranbaxy Laboratories Limited Formulation de divalproex de sodium a liberation prolongee
US20120178810A1 (en) * 2006-09-11 2012-07-12 Tailor Prakash Boya Extended release formulation of an antiepileptic agent
US20100172982A1 (en) * 2007-05-23 2010-07-08 Sun Pharmaceutical Industries Limited Sustained release formulations of divalproex sodium

Also Published As

Publication number Publication date
WO2017163268A3 (fr) 2018-01-11

Similar Documents

Publication Publication Date Title
CA2740146C (fr) Formes posologiques a liberation immediate d'oxybate de sodium
EP3287124B1 (fr) Forme posologique orale de kétamine
CN102946869B (zh) γ-羟基丁酸的速释制剂及剂型
US20140348917A1 (en) Immediate release formulations and dosage forms of gamma-hydroxybutyrate
EP3313187B1 (fr) Formulation à libération prolongée et comprimés préparés à partir de celle-ci
TW201328722A (zh) 醫藥調配物
AU2019321583B2 (en) Formulations of AG10
WO2019073477A1 (fr) Composition pharmaceutique d'aprémilast à libération prolongée
WO2020138791A2 (fr) Préparation à libération prolongée comprenant du tofacitinib ou un sel pharmaceutiquement acceptable associé et son procédé de fabrication
JP2022534159A (ja) 微細化した固形メラトニン組成物
EP4103158B1 (fr) Composition comprenant du ramipril et de l'indapamide
US9192615B2 (en) Method for the treatment of acne and certain dosage forms thereof
WO2022138717A1 (fr) Préparation solide orale
WO2009027786A2 (fr) Formes posologiques matricielles de varénicline
CN108420798A (zh) 一种抗凝剂的速释药物制剂及其制备方法
CN105311635A (zh) 可调控释放度的高载药量的医药组合物及其制备方法
WO2019076966A1 (fr) Comprimés comprenant de la tamsulosine et de la solifénacine
WO2017163268A2 (fr) Forme d'administration pharmaceutique du divalproex à libération prolongée
US20170273923A1 (en) Method of administering divalproex
KR20250041176A (ko) 나포라페닙을 포함하는 무정형 고체 분산물
CN119365195A (zh) 含有匹米替比的医药组合物
JP2003300874A (ja) 塩酸プソイドエフェドリン含有固形製剤
US20220175774A1 (en) Bioavailable Oral Dosage Form Of Tyrosine-Kinase Inhibitor
KR20150137272A (ko) 안정한 프레가발린 제어 방출성 서방형 제약 조성물 및 그 제조방법
WO2017114597A1 (fr) Formes pharmaceutiques comprenant du ((cis)-n-(4-(diméthylamino) -1,4-diphénylcyclohexyl)-n-méthylcinnamamide

Legal Events

Date Code Title Description
NENP Non-entry into the national phase in:

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17769578

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 17769578

Country of ref document: EP

Kind code of ref document: A2